In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II

Japanese Journal of Cancer Research

Volumn 90, Issue 5, 1999, Pages 578-587

  Aoyagi, Yoshimi ^a   Kobunai, Takashi ^a   Utsugi, Teruhiro ^a   Oh Hara, Tomoko ^b   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Cytotoxicity; Drug resistance; Quinoline derivative; TAS 103; Topoisomerase

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CISPLATIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; PROTEIN; RNA; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA PROTEIN COMPLEX; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG RESISTANCE; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS;

EID: 0033066292     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00786.x     Document Type: Article

References (40)

1. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T. and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
2. Matsuo, K., Kohno, K., Takano, H., Sato, S., Kiue, A. and Kuwano, M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res., 50, 5919-5824 (1990).
3. Long, B. H., Wang, L., Lorico, A., Wang, R. C. C., Brattain, M. G. and Casazza, A. M. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res., 51, 5275-5284 (1991).
4. Kubota, N., Nishio, K., Takeda, Y., Ohmori, T., Funayama, Y., Ogasawara, H., Ohira, T., Kunikake, H., Terashima, Y. and Saijo, N. Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother. Pharmacol., 34, 183-190 (1994).
5. Tamura, H., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Patterson, E., Keene, D. J., Okada, K., Kjeidsen, E., Nishikawa, K. and Andho, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res., 19, 69-75 (1991).
6. Kubota, N., Kanzawa, F., Nishio, K., Takeda, Y., Ohmori, T., Fujiwara, Y., Terashima, Y. and Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
7. Bugg, B. Y., Danks, M. K., Beck, W. T. and Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88, 7654-7658 (1991).
8. Minato, K., Kanazawa, F., Nishio, K., Nakagawa, K., Fujiwara, Y. and Saijo, N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother. Pharmacol., 26, 313-317 (1990).
9. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. and Sato, K. Intracellular roles of SN-38, metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51, 4187-4191 (1991).
10. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F. and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50, 7962-7965 (1990).
11. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T. and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50, 760-766 (1992).
12. Whitacre, C. M., Zborowska, E., Gohdon, N. H., Mackay, W. and Berger, N. A. Topotecan increases topoisomerase II α levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res., 57, 1425-1428 (1997).
13. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S. and Miura, Y. Effects of CPT-11 in combination with other anti-cancer agent in culture. Int. J. Cancer, 50, 604-610 (1992).
14. Bertrand, R., O'Connor, P. M., Kerrigan, D. and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer, 28A, 743-748 (1992).
15. Bonner, J. A. and Kozelsky, T. F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol., 39, 109-112 (1996).
16. Tolcher, A. W. A phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubucin (a topoisomerase II inhibitor). Proc. Am. Soc. Clin. Oncol., 13, 422 (1994).
17. Saijo, N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan. Ann. N. Y. Acad. Sci., 803, 292-305 (1996).
18. Utsugi, T., Aoyagi, K., Asao, T., Okazaki, S., Aoyagi, Y., Sano, M., Wierzba, K. and Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerase I and II. Jpn. J. Cancer Res., 88, 992-1002 (1997).
19. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S. and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990).
20. Saotome, T., Morita, H. and Umeda, M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxic. in Vitro, 3, 317-321 (1989).
21. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
22. Zwelling, L. A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., Parker, E., Silberman, L., Redcliffe, A., Beran, M. and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. J. Biol. Chem., 264, 16411-16420 (1989).
23. Ozawa, S., Sugiyama, Y., Mitsuhashi, J. and Inaba, M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res., 49, 3823-3828 (1989).
24. Inaba, M., Mitsuhashi, J., Kawada, S. and Nakano, H. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn. J. Cancer Res., 85, 187-193 (1994).
25. Sone, S., Ishii, K. and Tsuruo, T. Augmentation of 1-β-D-Arabinofuranosylcytosine resistance in human KB epidermoid carcinoma cells upon induction of a second resistance to vincristine. Cancer Res., 46, 3099-3104 (1986).
26. Fairchild, C. R., Ivy, S. P., Kao-Shan, C., Whang-Peng, J., Rosen, M., Israel, M. A., Melera, P. W., Cowan, K. H. and Goldsmith, M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res., 47, 5141-5148 (1987).
27. Hong, W, S., Saijo, S., Sasaki, Y., Minato, K., Nakano, H., Nakagawa, K., Fujiwara, Y., Nomura, K. and Twentyman, P. R. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int. J. Cancer, 41, 462-467 (1988).
28. Bungo, M., Fujiwara, Y., Kasahara, K., Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S. and Saijo, N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50, 2549-2553 (1990).
29. Ohmori, T., Morikage, T., Sugimoto, Y., Fujiwara, Y., Kasahara, K., Nishio, K., Ohta, S., Sasaki, Y., Takahashi, T. and Saijo, N. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn. J. Cancer Res., 84, 83-92 (1993).
30. Johnston, P. G., Drake, J. C., Trepel, J. and Allegra, C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res., 52, 4306-4312 (1992).
31. D'Arpa, P., Beadmore, C. and Liu, L. E. Involvement of nucleic acid synthesis in cell killing mechanism of topoisomerase poisons. Cancer Res., 50, 6919-6924 (1990).
32. Hsiang, Y., Lihou, M. G. and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49, 5077-5082 (1989).
33. Roberge, M., Th'ng, J., Hamaguchi, J. and Bradbury, E. M. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histone Hi and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells. J. Cell Biol, 111, 1753-1762 (1990).
34. Taagepera, S., Rao, P. N., Drake, F. H. and Gorbsky, G. J. DNA topoisomerase IIα is the major chromosome protein recognized by the mitolic phosphoprotein antibody MPM-2. Proc. Natl. Acad. Sci. USA, 90, 8407-8411 (1993).
35. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K. and Drake, F. H. Proliferation-and cell cycle-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2, 209-214 (1991).
36. Prosperi, E., Marchese, G. and Astaldi-Ricotti, G. C. B. Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes. Cell Prolif., 27, 257-267 (1994).
37. Poot, M., Hiller, K. H., Heimpel, S. and Hoehn, H. Distinct patterns of cell cycle distribution elicited by compounds interfering with DNA topoisomerase I and II activity. Exp. Cell Res., 218, 326-330 (1995).
38. Bino, G. D., Skierski, J. S. and Darzynkiewicz, Z. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Exp. Cell Res., 195, 485-491 (1991).
39. Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., Cowan, K., Wendel, K. and Burke, P. J. Topoisomerase II level and drug sensitivity in adult acute myelogenous leukemia. Blood, 83, 517-530 (1994).
40. Takatani, H., Oka, M., Fukuda, M., Narasaki, F., Nakano, R., Ikeda, K., Terashi, K., Kinoshita, A., Soda, H., Kanda, T., Schneider, E. and Kohno, S. Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas. Jpn. J. Cancer Res., 88, 160-165 (1997).